Dystrophic epidermolysis bullosa

Dystrophic epidermolysis bullosa is one of the major forms of a group of conditions called epidermolysis bullosa. Epidermolysis bullosa cause the skin to be very fragile and to blister easily. Blisters and skin erosions form in response to minor injury or friction, such as rubbing or scratching. The signs and symptoms of dystrophic epidermolysis bullosa vary widely among affected individuals. In mild cases, blistering may primarily affect the hands, feet, knees, and elbows. Severe cases of this condition involve widespread blistering that can lead to vision loss, scarring, and other serious medical problems.

Researchers classify dystrophic epidermolysis bullosa into major types based on the inheritance pattern and features of the condition. Although the types differ in severity, their features overlap significantly and they are caused by mutations in the same gene.

Recessive dystrophic epidermolysis bullosa severe generalized (RDEB-sev gen) is the classic form of the condition and is the most severe. Affected infants are typically born with widespread blistering and areas of missing skin, often caused by trauma that occurs during birth. Most often, blisters are present over the whole body and affect mucous membranes such as the moist lining of the mouth and digestive tract. As the blisters heal, they result in severe scarring. Scarring in the mouth and esophagus can make it difficult to chew and swallow food, leading to chronic malnutrition and slow growth. Additional complications of ongoing scarring can include fusion of the skin between the fingers and toes, loss of fingernails and toenails, joint deformities (contractures) that restrict movement, and eye inflammation leading to vision loss. Additionally, people with RDEB-sev gen have a very high risk of developing a form of skin cancer called squamous cell carcinoma in young adulthood. In these individuals, the cancer tends to be unusually aggressive and is often life-threatening.

Other types of recessive dystrophic epidermolysis bullosa fall along a spectrum referred to as RDEB-generalized and localized (RDEB-gen and -loc). These forms of the condition are somewhat less severe than RDEB-sev gen and are distinguished by the affected regions of the body. Blistering is often limited to the hands, feet, knees, and elbows in mild cases, but may be widespread in more severe cases. Rare forms affect specific regions of the body, such as the shins or the abdomen. Affected people often have malformed fingernails and toenails. The RDEB-gen and -loc types involve scarring in the areas where blisters occur, but these forms of the condition do not cause the severe scarring characteristic of RDEB-sev gen.

Another major type of this condition is known as dominant dystrophic epidermolysis bullosa (DDEB). The signs and symptoms of this condition tend to be milder than those of the recessive forms, with blistering often limited to the hands, feet, knees, and elbows. The blisters heal with scarring, but it is less severe than in recessive forms of
this condition. Most affected people have malformed fingernails and toenails, and the nails may be lost over time. In the mildest cases, abnormal nails are the only sign of the condition.

**Frequency**

Considered together, the prevalence of recessive and dominant dystrophic epidermolysis bullosa is estimated to be 3.3 per million people.

**Causes**

Mutations in the *COL7A1* gene cause all forms of dystrophic epidermolysis bullosa. This gene provides instructions for making a protein that forms the pieces (subunits) of a larger protein called type VII collagen. Collagens are proteins that give structure and strength to connective tissues, such as skin, tendons, and ligaments, throughout the body. Type VII collagen plays an important role in strengthening and stabilizing the skin. It is the main component of structures called anchoring fibrils, which anchor the top layer of skin, called the epidermis, to an underlying layer called the dermis.

*COL7A1* gene mutations alter the structure or disrupt the production of the type VII collagen subunit protein. These changes affect the production of type VII collagen. Mutations that severely reduce or prevent the production of type VII collagen cause RDEB-sev gen. Mutations that allow a small amount of normal or partially functional type VII collagen to be produced lead to milder forms of the dystrophic epidermolysis bullosa. When type VII collagen is abnormal or missing, the formation of anchoring fibrils is impaired. A shortage of these fibrils disrupts the connection of the epidermis to the dermis, and friction or other minor trauma can cause the two skin layers to separate. This separation leads to the formation of blisters, which can cause extensive scarring as they heal. Researchers are working to determine how abnormalities of type VII collagen also underlie the increased risk of skin cancer seen in RDEB-sev gen.

**Inheritance Pattern**

Recessive dystrophic epidermolysis bullosa (RDEB-sev gen and RDEB-gen and -loc) is inherited in an autosomal recessive pattern. Autosomal recessive inheritance means that both copies of the *COL7A1* gene in each cell have mutations. Most often, the parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but do not show signs and symptoms of the condition.

DDEB has an autosomal dominant pattern of inheritance. Autosomal dominant inheritance means that one copy of the altered gene in each cell is sufficient to cause the disorder. About 70 percent of all people with DDEB have inherited an altered *COL7A1* gene from an affected parent. The remaining 30 percent of affected people have the condition as a result of a new mutation in the *COL7A1* gene. These cases occur in people with no history of the disorder in their family.
Other Names for This Condition

- DEB
- epidermolysis bullosa dystrophica
- epidermolysis bullosa, dystrophic

Diagnosis & Management

Genetic Testing Information

- What is genetic testing?
  [primer/testing/genetictesting]
- Genetic Testing Registry: Dystrophic epidermolysis bullosa
- Genetic Testing Registry: Generalized dominant dystrophic epidermolysis bullosa
- Genetic Testing Registry: Recessive dystrophic epidermolysis bullosa

Research Studies from ClinicalTrials.gov

- ClinicalTrials.gov
  https://clinicaltrials.gov/ct2/results?cond=%22Epidermolysis+Bullosa+Dystrophica%22+OR+%22dystrophic+epidermolysis+bullosa%22

Other Diagnosis and Management Resources

- GeneReview: Dystrophic Epidermolysis Bullosa
  https://www.ncbi.nlm.nih.gov/books/NBK1304
- MedlinePlus Encyclopedia: Epidermolysis bullosa
  https://medlineplus.gov/ency/article/001457.htm
- MedlinePlus Encyclopedia: Squamous Cell Skin Cancer
  https://medlineplus.gov/ency/article/000829.htm

Additional Information & Resources

Health Information from MedlinePlus

- Encyclopedia: Epidermolysis bullosa
  https://medlineplus.gov/ency/article/001457.htm
- Encyclopedia: Squamous Cell Skin Cancer
  https://medlineplus.gov/ency/article/000829.htm
- Health Topic: Skin Conditions
  https://medlineplus.gov/skinconditions.html
Genetic and Rare Diseases Information Center
• Dystrophic epidermolysis bullosa
  https://rarediseases.info.nih.gov/diseases/2150/dystrophic-epidermolysis-bullosa

Additional NIH Resources
• National Institute of Allergy and Infectious Diseases
  https://www.niams.nih.gov/health-topics/epidermolysis-bullosa

Educational Resources
• MalaCards: dominant dystrophic epidermolysis bullosa
  https://www.malacards.org/card/dominant_dystrophic_epidermolysis_bullosa
• MalaCards: recessive dystrophic epidermolysis bullosa
  https://www.malacards.org/card/recessive_dystrophic_epidermolysis_bullosa
• Orphanet: Dystrophic epidermolysis bullosa
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=303

Patient Support and Advocacy Resources
• DebRA UK
  https://www.debra.org.uk/
• Dystrophic Epidermolysis Bullosa Research Association of America (DebRA)
  https://www.debra.org/
• Epidermolysis Bullosa Center, Cincinnati Children's Hospital Medical Center
  https://www.cincinnatichildrens.org/service/e/epidermolysis-bullosa
• Epidermolysis Bullosa Medical Research Foundation
  https://ebmrf.org/
• National Organization for Rare Disorders (NORD)
  https://rarediseases.org/rare-diseases/epidermolysis-bullosa/
• Resource list from the University of Kansas Medical Center
  http://www.kumc.edu/gec/support/epidermo.html

Clinical Information from GeneReviews
• Dystrophic Epidermolysis Bullosa
  https://www.ncbi.nlm.nih.gov/books/NBK1304
Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28Epidermolysis+Bullosa+Dystrophica%5BMAJR%5D%29+AND+%28%28dystrophic+epidermolysis+bullosa%5BMTJAB%5D%29+OR+%2828epidermolysis+bullosa+dystrophica%5BMTJAB%5D%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+1080+days%22%5Bdp%5D

Catalog of Genes and Diseases from OMIM

- EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL DOMINANT
  http://omim.org/entry/131750
- EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE
  http://omim.org/entry/226600

Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14726937
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14987265
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11260188
- Dystrophic Epidermolysis Bullosa Research Association of America (DebRA)
  https://www.debra.org/
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24690439
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27463098
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14616374
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20301481
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26029334  
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445895/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15708287

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16971478  
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2598021/

Reprinted from Genetics Home Reference:  

Reviewed: February 2020  
Published: February 11, 2020

Lister Hill National Center for Biomedical Communications  
U.S. National Library of Medicine  
National Institutes of Health  
Department of Health & Human Services